News Abingworth 'will launch $1.5bn fund for co-developed drugs' Abingworth is reported to be raising $1.5bn for further risk-sharing, royalty-bearing development deals with large pharma groups.
News Takeda signs deal with UK biotech GammaDelta Therapeutics on... UK biotech pioneering new type of T cell immunotherapy
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
